Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00073307
Registration number
NCT00073307
Ethics application status
Date submitted
19/11/2003
Date registered
21/11/2003
Date last updated
6/02/2014
Titles & IDs
Public title
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Query!
Scientific title
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.
Query!
Secondary ID [1]
0
0
11213
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sorafenib (Nexavar, BAY43-9006)
Treatment: Drugs - Placebo
Experimental: Sorafenib (Nexavar, BAY43-9006) - Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
Placebo comparator: Placebo - Placebo tablets matching in appearance were to be orally administered twice a day.
Treatment: Drugs: Sorafenib (Nexavar, BAY43-9006)
Multi Kinase Inhibitor
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population
Query!
Assessment method [1]
0
0
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.
Query!
Timepoint [1]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
Query!
Primary outcome [2]
0
0
Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population
Query!
Assessment method [2]
0
0
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.
Query!
Timepoint [2]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
Query!
Secondary outcome [1]
0
0
Final Progression-Free Survival (PFS) - Independent Radiological Review
Query!
Assessment method [1]
0
0
PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions.
Query!
Timepoint [1]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
Query!
Secondary outcome [2]
0
0
Best Overall Response - Independent Radiological Review
Query!
Assessment method [2]
0
0
Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated.
Query!
Timepoint [2]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
Query!
Secondary outcome [3]
0
0
Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment
Query!
Assessment method [3]
0
0
Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from "0=not at all" to "4=very much" and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL.
Query!
Timepoint [3]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
Query!
Secondary outcome [4]
0
0
Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment
Query!
Assessment method [4]
0
0
Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from "0=not at all" to "4=very much" and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL.
Query!
Timepoint [4]
0
0
From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
Query!
Eligibility
Key inclusion criteria
* Patients with unresectable and/or metastatic, measurable renal cell carcinoma histologically or cytologically documented
* Patients must have had one prior systemic therapy for advanced disease, which was completed at least 30 days but no longer than 8 months prior to randomization
* Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)
* Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1
* Patients who have adequate coagulation, liver and kidney functions
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients with rare subtypes of renal cell carcinoma (RCC) such as pure papillary cell tumors, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors
* Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma,or superficial bladder tumors, or other malignancies curatively treated > 2 years prior to entry
* Cardiac arrhythmias requiring anti-arrhythmics, symptomatic coronary artery disease or ischemia or congestive heart failure
* Patients with a history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
* Patients with a history or presence of metastatic brain or meningeal tumors
* Patients with seizure disorder requiring medication (such as anti-epileptics)
* History of organ allograft or bone marrow transplant of stem cell rescue
* Patients who are pregnant or breast-feeding Women of childbearing potential must have a negative pregnancy test prior to drug administration. Both men and women enrolled in this trial must use adequate birth control
* Patients who have three or more of the following:
* ECOG performance status greater than or equal to 2,
* Abnormally high lactate dehydrogenase,
* Abnormally high serum hemoglobin,
* Abnormally high corrected serum calcium,
* Absence of prior nephrectomy
* Excluded therapies and medications, previous and concomitant:
* Concurrent anti-cancer chemotherapy, immunotherapy or hormonal therapy except biphosphonates
* Significant surgery with 4 weeks of start of study
* Investigational drug therapy during or within 30 days
* Concomitant treatment with rifampin or St. John's Wort
* Prior use of Raf-kinase inhibitors (RKI), MEK or Farnesyl transferase inhibitors
* Prior use of Bevacizumab, and all other drugs (investigational or licensed) that target VEGF/VEGF receptors
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
903
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,VIC
Query!
Recruitment hospital [1]
0
0
- Garran
Query!
Recruitment hospital [2]
0
0
- Camperdown
Query!
Recruitment hospital [3]
0
0
- Liverpool
Query!
Recruitment hospital [4]
0
0
- Westmead
Query!
Recruitment hospital [5]
0
0
- Heidelberg
Query!
Recruitment hospital [6]
0
0
- Wodonga
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
0390 - Wodonga
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Wisconsin
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Santa Fe
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Capital Federal-Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Mendoza
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Bruxelles - Brussel
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Parana
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Rio Grande do Sul
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Alberta
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Ontario
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Quebec
Query!
Country [32]
0
0
Chile
Query!
State/province [32]
0
0
Santiago de Chile
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Bordeaux
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Caen Cedex 5
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lille Cedex
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Lyon Cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Marseille
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Nantes
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Paris Cedex 15
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Strasbourg
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Toulouse
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Villejuif
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Baden-Württemberg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Bayern
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Hessen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Nordrhein-Westfalen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Sachsen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Hamburg
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Budapest
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Debrecen
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Zalaegerszeg
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Haifa
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Aviv
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Milano
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Modena
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Pavia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Perugia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Reggio Emilia
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Roma
Query!
Country [61]
0
0
Netherlands
Query!
State/province [61]
0
0
Nijmegen
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Gdansk
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Krakow
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Lodz
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Lublin
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Poznan
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Szczecin
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Warszawa
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Wroclaw
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Barnaul
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Kazan
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Kirov
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Moscow
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Obninsk
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
St. Petersburg
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Freestate
Query!
Country [77]
0
0
South Africa
Query!
State/province [77]
0
0
Gauteng
Query!
Country [78]
0
0
South Africa
Query!
State/province [78]
0
0
Kwazulu-Natal
Query!
Country [79]
0
0
South Africa
Query!
State/province [79]
0
0
Western Cape
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Bilbao
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Barcelona
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Madrid
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Valencia
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Donetsk
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Kharkiv
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Kiev
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Lviv
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Poltava
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Middlesex
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
South Glamorgan
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Stratchclyde
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Surrey
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Tyne and Wear
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
West Midlands
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Amgen
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00073307
Query!
Trial related presentations / publications
Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr;78(1):24-32. doi: 10.1016/j.critrevonc.2010.03.006. Epub 2010 Apr 18. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22. Negrier S, Jager E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep;27(3):899-906. doi: 10.1007/s12032-009-9303-z. Epub 2009 Sep 12. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010 Oct 1;16(19):4853-63. doi: 10.1158/1078-0432.CCR-09-3343. Epub 2010 Jul 22. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63. doi: 10.1093/jnci/djn319. Epub 2008 Oct 7. Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007 Jun;30(3):220-7. doi: 10.1097/01.coc.0000258732.80710.05. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655. Erratum In: N Engl J Med. 2007 Jul 12;357(2):203. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249. Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclere J, Roche A, Lassau N. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006 Oct;42(15):2472-9. doi: 10.1016/j.ejca.2006.04.023. Epub 2006 Sep 11. Erratum In: Eur J Cancer. 2007 May;43(8):1336. Quintanilha JCF, Geyer S, Etheridge AS, Racioppi A, Hammond K, Crona DJ, Pena CE, Jacobson SB, Marmorino F, Rossini D, Cremolini C, Sanoff HK, Abou-Alfa GK, Innocenti F. KDR genetic predictor of toxicities induced by sorafenib and regorafenib. Pharmacogenomics J. 2022 Dec;22(5-6):251-257. doi: 10.1038/s41397-022-00279-3. Epub 2022 Apr 28. Quintanilha JCF, Racioppi A, Wang J, Etheridge AS, Denning S, Pena CE, Skol AD, Crona DJ, Lin D, Innocenti F. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. Pharmacogenomics J. 2022 Feb;22(1):82-88. doi: 10.1038/s41397-021-00261-5. Epub 2021 Nov 13. Erratum In: Pharmacogenomics J. 2022 Mar;22(2):145. doi: 10.1038/s41397-021-00264-2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Antoun S, Birdsell L, Sawyer MB, Venner P, Escudie...
[
More Details
]
Journal
Bellmunt J, Eisen T, Fishman M, Quinn D. Experienc...
[
More Details
]
Journal
Massard C, Zonierek J, Gross-Goupil M, Fizazi K, S...
[
More Details
]
Journal
Negrier S, Jager E, Porta C, McDermott D, Moore M,...
[
More Details
]
Journal
Pena C, Lathia C, Shan M, Escudier B, Bukowski RM....
[
More Details
]
Journal
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudar...
[
More Details
]
Journal
Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H...
[
More Details
]
Journal
Bukowski R, Cella D, Gondek K, Escudier B; Sorafen...
[
More Details
]
Journal
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudar...
[
More Details
]
Journal
Kane RC, Farrell AT, Saber H, Tang S, Williams G, ...
[
More Details
]
Journal
Lamuraglia M, Escudier B, Chami L, Schwartz B, Lec...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00073307
Download to PDF